Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LAT 8881 -Lateral Pharma

Drug Profile

LAT 8881 -Lateral Pharma

Alternative Names: Advanced Obesity Drug 9604; AOD9604; LAT-8881; Tyr-hGH171191

Latest Information Update: 14 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Monash University
  • Developer Lateral Pharma Pty Ltd; Metabolic Pharmaceuticals
  • Class Analgesics; Antimigraines; Peptide fragments; Peptide hormones
  • Mechanism of Action Neuron inhibitors; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Migraine; Neuropathic pain
  • Phase I Pain
  • No development reported Osteoporosis
  • Discontinued Obesity

Most Recent Events

  • 16 Jun 2023 Lateral Pharma completes a phase I trial for Pain (In adults) in Australia in (IV, infusion) (NCT05298306)
  • 17 May 2022 Phase-I clinical trials in Pain (Radiculopathy lumbar) in Australia (IV) (NCT05298306)
  • 28 Mar 2022 Lateral Pharma plans a phase I trial for Lumbar radicular pain (IV, infusion) in Australia in March 2022 (NCT05298306)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top